Climb Bio, Inc. filed a Form 8-K with the SEC on September 3, 2026, disclosing positive results from its ongoing Phase 1 trial of CLYM116 and providing a strategy update for development in IgA nephropathy.

Key Highlights

  • Positive Phase 1 results: Climb Bio announced positive results from its ongoing Phase 1 trial evaluating CLYM116, an anti-APRIL monoclonal antibody.
  • Target indication: The trial and strategy update focus on IgA nephropathy as the development target for CLYM116.
  • Press release and presentation published: A press release and corporate presentation, both dated September 3, 2026, were furnished as Exhibits 99.1 and 99.2 respectively.
  • Emerging growth company: Climb Bio, Inc. is classified as an emerging growth company under applicable SEC rules.
  • Signed by CEO: The filing was signed by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer.

Climb Bio Discloses CLYM116 Phase 1 Data and IgA Nephropathy Development Strategy

According to the filing, Climb Bio, Inc. (NASDAQ:CLYM) issued a press release and published a corporate presentation on September 3, 2026, announcing positive results from its ongoing Phase 1 trial. The trial is evaluating CLYM116, which the company describes as an anti-APRIL monoclonal antibody, in patients with IgA nephropathy. The filing also notes that the company provided updates on its strategy for further development in that indication.

The filing was made under Item 7.01, Regulation FD Disclosure. As the company disclosed, the information furnished under Item 7.01, including Exhibits 99.1 and 99.2, "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and is not incorporated by reference into other filings under the Exchange Act or the Securities Act. The filing does not provide the specific clinical data points, patient enrollment numbers, or endpoints from the Phase 1 trial; those details are contained in the attached press release and investor presentation furnished as exhibits.

Climb Bio is headquartered at 20 William Street, Suite G50, Wellesley Hills, Massachusetts 02481. Its common stock, par value $0.0001 per share, is listed on the Nasdaq Global Market under the trading symbol CLYM. The company is incorporated in Delaware and holds Commission File Number 001-40708.

What Was Disclosed

Climb Bio filed an 8-K on September 3, 2026, reporting positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody being studied in IgA nephropathy, and furnished a press release and corporate presentation as exhibits.